Skip to main content

Semaglutide and liraglutide for alcohol use disorder (AUD)

Medically reviewed by Carmen Pope, BPharm. Last updated on May 14, 2025.

Official Answer by Drugs.com

GLP-1 receptor agonist medications, such as semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza) commonly prescribed for type 2 diabetes and obesity, may offer a promising new approach for treating Alcohol Use Disorder (AUD). Recent research from at least two large clinical trials suggests these medications significantly reduce alcohol consumption and related hospitalizations. These clinical trials support prior research that reported that weekly GLP-1 medications reduced alcohol cravings, drinking frequency, and alcohol intake.

For high consumers of alcohol, the reduction in intake with GLP-1 medications was approximately 68%, from 23.2 units to 7.8 units/week. Alcohol use in low consumers reduced from 5.5 to 2.5 units/week. Many people report the effects of GLP-1 drugs at reducing alcohol cravings was “effortless”, saying they were able to cut down their drinking without even really thinking about it.

In the US, over 28 million people aged 12 and older are diagnosed with AUD each year, including 757,000 adolescents aged 12-17 years. New treatments for AUD are needed because current AUD medications such as disulfiram, acamprosate, or naltrexone are difficult to access, underutilized, and sometimes have unpleasant side effects.

How do GLP-1 drugs reduce alcohol use?

Research indicates that GLP-1 receptors are distributed throughout brain regions involved in reward processing and addictive behaviors. When these receptors are activated, studies have observed a corresponding decrease in alcohol consumption patterns and a diminished dopamine response to alcohol.

This occurs because GLP-1 receptor stimulation appears to modify dopamine transmission within the brain's reward pathways. Multiple clinical investigations have demonstrated that individuals receiving GLP-1 medications report diminished urges to drink and consume less alcohol overall.

Scientists theorize that these effects stem from how these medications influence neural circuits controlling reward perception, satisfaction, and the feeling of fullness, potentially addressing both metabolic and addictive processes simultaneously.

Related questions

Latest evidence

Significant reductions in alcohol consumption were reported in 262 patients (79% female, mean age 46) treated with the GLP-1 receptor agonists, semaglutide or liraglutide for obesity, in a prospective observational study published in the journal, Diabetes, Obesity, and Metabolism.

These findings suggest GLP-1 receptor agonists may offer dual benefits for patients with comorbid obesity and alcohol use disorder, potentially providing an integrated treatment approach.

Evidence from the Swedish Cohort Study

Semaglutide and liraglutide significantly lowered the risk of alcohol-related hospital admissions in those with AUD in a large Swedish cohort study (227,000 people) published in JAMA Psychiatry. These treatments also help reduce admissions for substance use disorder (SUD).

Patients with comorbid conditions such as type 2 diabetes or obesity, in addition to AUD, benefited the most from these treatments.

Comparative Effectiveness

Semaglutide showed the strongest results:

Liraglutide demonstrated the second-best results:

Would Mounjaro also work for AUD?

Although Mounjaro (tirzepatide) hasn't been as extensively studied as semaglutide and liraglutide for AUD, its dual-receptor mechanism might potentially offer similar or even enhanced effects on reducing alcohol consumption by influencing reward circuitry in the brain.

References
  • Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry. 2025;82(1):94–98. doi:10.1001/jamapsychiatry.2024.3599
  • Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. Published online February 12, 2025. doi:10.1001/jamapsychiatry.2024.4789
  • O'Farrell M, Almohaileb FI, le Roux CW. Glucagon-like peptide-1 analogues reduce alcohol intake. Diabetes Obes Metab. 2025; 27(3): 1601-1604. doi:10.1111/dom.16152

Read next

Tirzepatide vs semaglutide: How do they compare?

Both tirzepatide and semaglutide are prescription medicines used with diet and exercise to treat people with type 2 diabetes or to help people lose and maintain weight loss. Tirzepatide is also approved by the FDA to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity, while semaglutide is approved to reduce the risk of serious heart problems and to help reduce the risk of worsening kidney disease.

Continue reading

Can you get tirzepatide from a compounding pharmacy?

Tirzepatide cannot be legally compounded in a U.S. pharmacy at this time. It has been removed from the FDA drug shortage list as of October 2, 2024. When drugs are in short supply, the FDA may allow temporary compounding of some medicines to allow patients to continue to access their treatments. Tirzepatide is now widely available as a prescription medicine made by Eli Lilly under the brands names Mounjaro (for type 2 diabetes) and Zepbound (for weight loss and sleep apnea).

Continue reading

Why am I not losing weight on Ozempic?

Although Ozempic is not FDA-approved for weight loss, over 86% of people lose at least 5% of their body weight in trials that have studied semaglutide, the active ingredient of Ozempic. But the same clinical trials also show that just under 14% don’t lose weight, and some may even gain weight. Continue reading

See also:

Related medical questions

Drug information

Related support groups